ADMS (Mkap $104 M) Cash $160 M / MS Walking P3 Data dieses Quartal - 500 Beiträge pro Seite
eröffnet am 14.10.19 16:58:11 von
neuester Beitrag 11.10.21 13:38:17 von
neuester Beitrag 11.10.21 13:38:17 von
Beiträge: 19
ID: 1.313.710
ID: 1.313.710
Aufrufe heute: 0
Gesamt: 4.163
Gesamt: 4.163
Aktive User: 0
ISIN: US00548A1060 · WKN: A111X7
8,2200
USD
+0,74 %
+0,0600 USD
Letzter Kurs 24.11.21 NYSE
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5800 | +922,86 | |
| 0,5400 | +38,46 | |
| 1,9900 | +32,67 | |
| 5,4000 | +27,06 | |
| 1,8250 | +25,86 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 14,510 | -32,32 | |
| 3,6400 | -38,62 | |
| 0,5660 | -40,42 | |
| 1,7700 | -46,69 | |
| 84,75 | -74,50 |
Feedback
Heißer und Unterbewerteter Zock für das 4Q, in Kürze werden Phase 3 Daten (MS walking Impairment) veröffentlicht falls positiv könnte das die Aktie ordentlich nach oben pushen $10 könnten drin sein .Adamas hat bereits ein eignes Produkt am Markt (dyskinesie bei parkinson) und ab Mai 2020 beginnt Allergan royalties an ADMS für Namzaric (alzheimer´s dementia) zu zahlen . Auch diese Aktie wurde brutal massakriert und bietet jetzt knapp über dem Allzeittief eine große Chance für Zocker .
Phase 3 Daten (MS Walking) könnten jederzeit reinkommen das Medikament könnte Peak Sales von $500+ million erreichen .
Adamas Pharma (ADMS)
Marktkap:$104 M
Cash:$160 M
Kurs:$3.88
Aktienanzahl: 27,7 M
Presentation Oktober
http://ir.adamaspharma.com/static-files/882038bd-aa87-458c-8…
INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) enrollment completed, with topline results expected late Q4 2019
Adamas Pharmaceuticals is eligible to receive royalties on net sales of Namzaric beginning in May of 2020.
Phase 3 Daten (MS Walking) könnten jederzeit reinkommen das Medikament könnte Peak Sales von $500+ million erreichen .
Adamas Pharma (ADMS)
Marktkap:$104 M
Cash:$160 M
Kurs:$3.88
Aktienanzahl: 27,7 M
Presentation Oktober
http://ir.adamaspharma.com/static-files/882038bd-aa87-458c-8…
INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) enrollment completed, with topline results expected late Q4 2019
Adamas Pharmaceuticals is eligible to receive royalties on net sales of Namzaric beginning in May of 2020.
Antwort auf Beitrag Nr.: 61.688.611 von Biohero am 14.10.19 16:58:11ADMS ist auch ein attraktiver Übernahmekandidat , das Parkinson medikament hatten viele analysten als potentiellen Blockbuster angesehen aber Gocovri hat sich nicht sogut entwickelt wie erhofft deshalb der übertriebene Ausverkauf .Gocovri ist erst seit anfang letzten Jahres am Markt und die Umsätze steigen zwar langsam aber sie steigen , das ist ADMS erstes Produkt denke das da auch etwas unerfahrenheit im Spiel ist . Die Firma hat weitere attraktive Produkte in Pipeline und ist sehr niedrig bewertet .
The company is also poised to begin receiving royalty payments in the low to mid-teens millions on sales of dementia drug Namzaric beginning in May 2020. Allergan reported total sales of $93 million for the drug through the first nine months of 2018. In other words, the future looks promising for the punching bag named Adamas Pharmaceuticals.
Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
http://ir.adamaspharma.com/news-releases/news-release-detail…
The company is also poised to begin receiving royalty payments in the low to mid-teens millions on sales of dementia drug Namzaric beginning in May 2020. Allergan reported total sales of $93 million for the drug through the first nine months of 2018. In other words, the future looks promising for the punching bag named Adamas Pharmaceuticals.
Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
http://ir.adamaspharma.com/news-releases/news-release-detail…
Hi Biohero.
Wie lange reicht denn der Cashbestand?
Wie lange reicht denn der Cashbestand?
Bzw reichen die Royalties von allergan ab nächstes Jahr?
Antwort auf Beitrag Nr.: 61.699.423 von Aurcaner am 15.10.19 21:32:18Also verfügbares Geld soll bis ende 2020 reichen kann auch darüber hinaus gehen wenn sich Gocovri besser entwickelt und eventuell die kosten gesenkt werden .Aber solange hab ich sowieso nicht vor zu halten ich warte die Phase 3 daten ab und dann bin ich weg .
Trading Spotlight
Antwort auf Beitrag Nr.: 61.699.621 von Biohero am 15.10.19 21:53:46Vielleicht sehen wir die $5+ die Woche noch ....
Danke Biohero für deine Einschätzung.
Ich bin noch an der Seitenlinie
Ich bin noch an der Seitenlinie
Adamas to Announce Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019
Print
Adamas Pharmaceuticals (NASDAQ:ADMS)
Intraday Stock Chart
Today : Friday 1 November 2019
Click Here for more Adamas Pharmaceuticals Charts.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
Investor Conference Call and Webcast
The conference call can be accessed by dialing (844) 215-3280 for participants in the U.S. or Canada and (484) 747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at ir.adamaspharma.com/events-presentations and will be available for replay until February 25, 2019.
Adamas Pharmaceuticals (NASDAQ:ADMS)
Intraday Stock Chart
Today : Friday 1 November 2019
Click Here for more Adamas Pharmaceuticals Charts.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
Investor Conference Call and Webcast
The conference call can be accessed by dialing (844) 215-3280 for participants in the U.S. or Canada and (484) 747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at ir.adamaspharma.com/events-presentations and will be available for replay until February 25, 2019.
Antwort auf Beitrag Nr.: 61.707.169 von Biohero am 16.10.19 18:36:41Gibt es was neues Biohero? Hat sich ja gut gehalten und nun geht's langsam nach oben...!
Gruß
Gruß
Antwort auf Beitrag Nr.: 61.822.771 von Naggn am 02.11.19 19:50:37Hab heute ADMS abgestossen mit dem Geld werde ich entweder Pharmaxis oder Valbiotis aufstocken mal gucken .
Die laufen doch sehr gut.
@Biohero
Erwartest du morgen keine guten Zahlen oder gar ein update zu den Produkten.
@Biohero
Erwartest du morgen keine guten Zahlen oder gar ein update zu den Produkten.
Antwort auf Beitrag Nr.: 61.865.505 von _poseidon am 07.11.19 18:21:52Zahlen sind doch schon da:
Nov 7, 2019
- Third quarter GOCOVRI® product sales of $13.9 million; total prescriptions grew to approximately 6,640
- Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) expected second half December 2019
EMERYVILLE, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2019, as well as recent corporate developments.
“I’m impressed with the team we have in place and their commitment to develop and commercialize medicines intended to lessen the burden of chronic neurological diseases on patients, caregivers and society,” said Neil F. McFarlane, Chief Executive Officer. “We continue to identify and execute opportunities to advance GOCOVRI’s commercial performance for the benefit of Parkinson’s disease patients with dyskinesia and OFF. During the quarter, driven by new patients and strong persistence, total GOCOVRI prescriptions continued sequential quarter-over-quarter growth.” Mr. McFarlane continued, “In the second half of December, we plan to report topline data from our INROADS Phase 3 study of ADS-5102 for walking impairment in patients with multiple sclerosis. If successful, this potential second indication for GOCOVRI could be a valuable treatment option for these patients for whom walking impairment remains a significant unmet need.”
Adamas corporate update
Neil McFarlane joined Adamas as Chief Executive Officer in September 2019.
GOCOVRI commercialization updates
GOCOVRI product sales were $13.9 million in the third quarter of 2019, compared to $12.7 million in the second quarter of 2019.
GOCOVRI generated approximately 6,640 total prescriptions (TRx) in the third quarter of 2019, an 8% sequential increase over approximately 6,160 TRx in the second quarter of 2019. The number of new patients starting on GOCOVRI, primarily patients receiving medication through the free trial program, was approximately 710 in the third quarter, compared to 740 in the second quarter of 2019.
Continued strong patient persistence of 45%-50% at 12 months for GOCOVRI.
ADS-5102 development update
Topline results from the INROADS Phase 3 study of ADS-5102 for walking impairment in patients with multiple sclerosis (MS) are expected in the second half of December 2019.
Financial results
Product sales
GOCOVRI product sales were $13.9 million for the third quarter of 2019, up 31% compared to $10.6 million in the same period in 2018. GOCOVRI product sales were $38.3 million for the nine months ended September 30, 2019, up 85% compared to $20.7 million in the first nine months of 2018.
GOCOVRI received U.S. Food and Drug Administration (FDA) approval in August 2017, becoming the first and only U.S. FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. Adamas began commercial promotion of GOCOVRI in January 2018.
Research and Development (R&D) expenses
R&D expenses for the third quarter of 2019 were $6.0 million, compared to $11.7 million for the same period a year ago. For the nine months ended September 30, 2019, R&D expenses were $24.9 million, compared to $28.7 million for the nine months ended September 30, 2018. R&D expenses in both periods were primarily attributable to the INROADS Phase 3 study of ADS-5102 for the treatment of walking impairment in patients with MS.
Selling, General and Administrative (SG&A) expenses
SG&A expenses for the third quarter of 2019 were $31.2 million, compared to $27.5 million for the same period a year ago. For the nine months ended September 30, 2019, SG&A expenses were $84.1 million, compared to $81.6 million for the nine months ended September 30, 2018. SG&A expenses in both periods were primarily attributable to external and sales force costs related to GOCOVRI commercialization.
Net loss
Net loss was $27.6 million, or $0.99 per share, basic and diluted, for the third quarter of 2019, compared to a net loss of $33.2 million, or $1.22 per share, basic and diluted, for the third quarter of 2018. Net loss for the third quarters of 2019 and 2018 included $4.5 million and $4.1 million, respectively, in non-cash stock-based compensation expense. Net loss for the nine months ended September 30, 2019, was $82.1 million, or $2.97 per share, basic and diluted, compared with a net loss for the same period in 2018 of $102.1 million, or $3.82 per share, basic and diluted. The net loss for the first nine months of 2019 and 2018 included $10.8 million and $12.0 million, respectively, in non-cash stock-based compensation expense.
Cash and investments
As of September 30, 2019, Adamas had $150.2 million of cash, cash equivalents and available-for-sale securities, compared to $210.9 million at December 31, 2018.
Nov 7, 2019
- Third quarter GOCOVRI® product sales of $13.9 million; total prescriptions grew to approximately 6,640
- Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) expected second half December 2019
EMERYVILLE, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2019, as well as recent corporate developments.
“I’m impressed with the team we have in place and their commitment to develop and commercialize medicines intended to lessen the burden of chronic neurological diseases on patients, caregivers and society,” said Neil F. McFarlane, Chief Executive Officer. “We continue to identify and execute opportunities to advance GOCOVRI’s commercial performance for the benefit of Parkinson’s disease patients with dyskinesia and OFF. During the quarter, driven by new patients and strong persistence, total GOCOVRI prescriptions continued sequential quarter-over-quarter growth.” Mr. McFarlane continued, “In the second half of December, we plan to report topline data from our INROADS Phase 3 study of ADS-5102 for walking impairment in patients with multiple sclerosis. If successful, this potential second indication for GOCOVRI could be a valuable treatment option for these patients for whom walking impairment remains a significant unmet need.”
Adamas corporate update
Neil McFarlane joined Adamas as Chief Executive Officer in September 2019.
GOCOVRI commercialization updates
GOCOVRI product sales were $13.9 million in the third quarter of 2019, compared to $12.7 million in the second quarter of 2019.
GOCOVRI generated approximately 6,640 total prescriptions (TRx) in the third quarter of 2019, an 8% sequential increase over approximately 6,160 TRx in the second quarter of 2019. The number of new patients starting on GOCOVRI, primarily patients receiving medication through the free trial program, was approximately 710 in the third quarter, compared to 740 in the second quarter of 2019.
Continued strong patient persistence of 45%-50% at 12 months for GOCOVRI.
ADS-5102 development update
Topline results from the INROADS Phase 3 study of ADS-5102 for walking impairment in patients with multiple sclerosis (MS) are expected in the second half of December 2019.
Financial results
Product sales
GOCOVRI product sales were $13.9 million for the third quarter of 2019, up 31% compared to $10.6 million in the same period in 2018. GOCOVRI product sales were $38.3 million for the nine months ended September 30, 2019, up 85% compared to $20.7 million in the first nine months of 2018.
GOCOVRI received U.S. Food and Drug Administration (FDA) approval in August 2017, becoming the first and only U.S. FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. Adamas began commercial promotion of GOCOVRI in January 2018.
Research and Development (R&D) expenses
R&D expenses for the third quarter of 2019 were $6.0 million, compared to $11.7 million for the same period a year ago. For the nine months ended September 30, 2019, R&D expenses were $24.9 million, compared to $28.7 million for the nine months ended September 30, 2018. R&D expenses in both periods were primarily attributable to the INROADS Phase 3 study of ADS-5102 for the treatment of walking impairment in patients with MS.
Selling, General and Administrative (SG&A) expenses
SG&A expenses for the third quarter of 2019 were $31.2 million, compared to $27.5 million for the same period a year ago. For the nine months ended September 30, 2019, SG&A expenses were $84.1 million, compared to $81.6 million for the nine months ended September 30, 2018. SG&A expenses in both periods were primarily attributable to external and sales force costs related to GOCOVRI commercialization.
Net loss
Net loss was $27.6 million, or $0.99 per share, basic and diluted, for the third quarter of 2019, compared to a net loss of $33.2 million, or $1.22 per share, basic and diluted, for the third quarter of 2018. Net loss for the third quarters of 2019 and 2018 included $4.5 million and $4.1 million, respectively, in non-cash stock-based compensation expense. Net loss for the nine months ended September 30, 2019, was $82.1 million, or $2.97 per share, basic and diluted, compared with a net loss for the same period in 2018 of $102.1 million, or $3.82 per share, basic and diluted. The net loss for the first nine months of 2019 and 2018 included $10.8 million and $12.0 million, respectively, in non-cash stock-based compensation expense.
Cash and investments
As of September 30, 2019, Adamas had $150.2 million of cash, cash equivalents and available-for-sale securities, compared to $210.9 million at December 31, 2018.
Antwort auf Beitrag Nr.: 61.865.505 von _poseidon am 07.11.19 18:21:52War nicht wegen den Zahlen drin sondern wegen den bevorstehenden Phase 3 Daten ,hab verkauft weil Depot langsam anfing unübersichtlich zu werden und das mag ich nicht .
"Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) expected second half December 2019"
"As of September 30, 2019, Adamas had $150.2 million of cash, cash equivalents and available-for-sale securities"
"Topline results from INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) expected second half December 2019"
"As of September 30, 2019, Adamas had $150.2 million of cash, cash equivalents and available-for-sale securities"
Danke Biohero.
Darf ich fragen bei welchen Werten du aktuell noch investiert bist? Danke
Darf ich fragen bei welchen Werten du aktuell noch investiert bist? Danke
Antwort auf Beitrag Nr.: 61.879.158 von Badenfinke am 09.11.19 09:23:04moin,
hat einer news, die den anstieg +18% erklären?
liegt das nur am earning call? Ich hab nix anderes gefuden.
BG
hat einer news, die den anstieg +18% erklären?
liegt das nur am earning call? Ich hab nix anderes gefuden.
BG
Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences
Date : 11/21/2019 @ 9:02PM
Source : GlobeNewswire Inc.
Stock : Adamas Pharmaceuticals Inc (ADMS)
Quote : 6.5 0.35 (5.69%) @ 8:02PM
Weiss jemand um was es da ging ?
Date : 11/21/2019 @ 9:02PM
Source : GlobeNewswire Inc.
Stock : Adamas Pharmaceuticals Inc (ADMS)
Quote : 6.5 0.35 (5.69%) @ 8:02PM
Weiss jemand um was es da ging ?
Position verkauft .... Gibt schöne Weihnachtsgeschenke...
Allen investierten noch viel Glück hier.
Allen investierten noch viel Glück hier.
Morgen PDUFA 
2 Biotech Übernahmen heute einmal ADMS durch SUPN und FLXN durch PCRX ..
Supernus Pharma To Acquire Adamas Pharma For Total Consideration Up To $9.10/shr
https://www.rttnews.com/3231722/supernus-pharma-to-acquire-a…
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
https://www.globenewswire.com/news-release/2021/10/11/231171…
Supernus Pharma To Acquire Adamas Pharma For Total Consideration Up To $9.10/shr
https://www.rttnews.com/3231722/supernus-pharma-to-acquire-a…
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
https://www.globenewswire.com/news-release/2021/10/11/231171…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -1,39 | |
| -3,54 | |
| -1,46 | |
| +0,42 | |
| -3,41 | |
| -8,74 | |
| -59,48 | |
| -8,78 | |
| -3,27 | |
| -8,44 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 196 | ||
| 95 | ||
| 69 | ||
| 50 | ||
| 46 | ||
| 42 | ||
| 41 | ||
| 37 | ||
| 33 | ||
| 27 |
